<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00659165</url>
  </required_header>
  <id_info>
    <org_study_id>UNM HRRC # 08-043</org_study_id>
    <nct_id>NCT00659165</nct_id>
  </id_info>
  <brief_title>Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes</brief_title>
  <official_title>Exploration of the Weight Neutral Effects of Insulin Detemir Compared to Insulin Glargine: A Measure of Satiety and Calories Consumed in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with diabetes treated with insulin often gain weight, which may deter patients from
      adhering to insulin treatment. Detemir is one type of long acting insulin approved by the
      Food and Drug Administration for use in people with diabetes. It is similar to other long
      acting insulins (Neutral Protein Hagedorn [NPH], glargine) except that it has been associated
      with less weight gain compared to other types of insulin. The reasons for this are still
      unclear. One possibility is that detemir insulin acts differently than do other insulins in
      affecting how diabetic patients eat meals. The purpose of this study is to determine whether
      appetite and calories eaten during a meal are affected by the type of insulin used to treat
      diabetes. This is a pilot study which means we are gathering preliminary information to
      determine if a larger study can be done.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulin detemir is a neutral, soluble long acting insulin analog with weight neutral
      properties. In limited studies, it has been shown to result in less weight gain in type 1 and
      type 2 diabetics compared with other long acting insulin formations. A possible mechanism for
      its weight neutrality is the fatty acid chain that may allow for improved central nervous
      system activity and effects on satiety. The primary objective of this study is to determine
      if patients with type 1 diabetes consume fewer calories when allowed to eat to satiety while
      treated with insulin detemir compared to insulin glargine. Secondary objectives are 1)
      subject responses on validated satiety scales and food diaries, 2) bioelectrical impedance
      analysis, 3) resting energy expenditure on indirect calorimetry/metabolic cart measurement,
      and 4) centrally acting mediators of satiety measured in the serum (Peptide YY [PYY],
      ghrelin, leptin).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Calories Consumed After Fast.</measure>
    <time_frame>Measured after a 24 hour fast, after treatment with study insulin for at least 3 weeks</time_frame>
    <description>Total energy ingested following the 24 hour fast.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Insulin Detemir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin Detemir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin Glargine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Detemir</intervention_name>
    <description>Subjects will be given a dose of detemir equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.</description>
    <arm_group_label>Insulin Detemir</arm_group_label>
    <other_name>Levemir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Subjects will be given a dose of glargine equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.</description>
    <arm_group_label>Insulin Glargine</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes

          -  Treated with long-acting and meal time insulin therapy for at least 2 years

          -  Ages 18 to 60 years of age

          -  Glycosylated hemoglobin value between 7 - 9 mg/dL

          -  C-peptide value less than 1.0 pmol/ml 90 minutes after oral Boost Plus administration.

        Exclusion Criteria:

          -  Advanced complications of diabetes (nephropathy, retinopathy, significant neuropathy,
             coronary artery disease)

          -  Severe medical illness or medical conditions including congestive heart failure,
             angina, liver failure or renal failure

          -  Pregnancy

          -  Alcohol or drug abuse or dependence within three months of study entry

          -  Less than 50 % agreement on 50-item Food Questionnaire with the Food Array &quot;buffet
             style&quot; study meal.

          -  Women of child-bearing age not adhering to the following contraceptive methods: oral
             contraceptives, barrier methods including condoms or diaphragm, or abstinence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Burge, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico, Department of Internal Medicine, Division of Endocrinology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Mitchell, D.O.</last_name>
    <role>Study Director</role>
    <affiliation>University of New Mexico, Department of Internal Medicine, Division of Endocrinology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of New Mexico Health Sciences Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bush MA. Intensive diabetes therapy and body weight: focus on insulin detemir. Endocrinol Metab Clin North Am. 2007 Aug;36 Suppl 1:33-44. Review.</citation>
    <PMID>17881330</PMID>
  </reference>
  <reference>
    <citation>Drugdex System:Klasko RK: Detemir. Drugdex System. Thomson Micromedex, Greenwood Village, Colorado (2007).</citation>
  </reference>
  <reference>
    <citation>Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab. 2007 May;9(3):209-17. Review.</citation>
    <PMID>17391147</PMID>
  </reference>
  <reference>
    <citation>Wynne K, Stanley S, McGowan B, Bloom S. Appetite control. J Endocrinol. 2005 Feb;184(2):291-318. Review.</citation>
    <PMID>15684339</PMID>
  </reference>
  <reference>
    <citation>Tahbaz F, Kreis I, Calvert D. An audit of diabetes control, dietary management and quality of life in adults with type 1 diabetes mellitus, and a comparison with nondiabetic subjects. J Hum Nutr Diet. 2006 Feb;19(1):3-11.</citation>
    <PMID>16448469</PMID>
  </reference>
  <reference>
    <citation>Cruz AF, Calle-Pascual AL; Diabetes and Nutrition Study Group, Spanish Diabetes Association. Diabetes Nutrition and Complications Trial: Trends in nutritional pattern between 1993 and 2000 and targets of diabetes treatment in a sample of Spanish people with diabetes. Diabetes Care. 2004 Apr;27(4):984-7.</citation>
    <PMID>15047660</PMID>
  </reference>
  <reference>
    <citation>Toeller M, Buyken AE, Heitkamp G, Cathelineau G, Ferriss B, Michel G; EURODIAB IDDM Complications Study Group. Nutrient intakes as predictors of body weight in European people with type 1 diabetes. Int J Obes Relat Metab Disord. 2001 Dec;25(12):1815-22.</citation>
    <PMID>11781763</PMID>
  </reference>
  <reference>
    <citation>Wilding JP. Neuropeptides and appetite control. Diabet Med. 2002 Aug;19(8):619-27. Review.</citation>
    <PMID>12147141</PMID>
  </reference>
  <reference>
    <citation>McDuffie JR, Riggs PA, Calis KA, Freedman RJ, Oral EA, DePaoli AM, Yanovski JA. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab. 2004 Sep;89(9):4258-63.</citation>
    <PMID>15356018</PMID>
  </reference>
  <reference>
    <citation>Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord. 2000 Jan;24(1):38-48.</citation>
    <PMID>10702749</PMID>
  </reference>
  <reference>
    <citation>Stunkard AJ, Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985;29(1):71-83.</citation>
    <PMID>3981480</PMID>
  </reference>
  <reference>
    <citation>Pieber TR, Treichel HC, Hompesch B, Philotheou A, Mordhorst L, Gall MA, Robertson LI. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med. 2007 Jun;24(6):635-42. Epub 2007 Mar 22.</citation>
    <PMID>17381500</PMID>
  </reference>
  <reference>
    <citation>de Graaf C, Blom WA, Smeets PA, Stafleu A, Hendriks HF. Biomarkers of satiation and satiety. Am J Clin Nutr. 2004 Jun;79(6):946-61. Review.</citation>
    <PMID>15159223</PMID>
  </reference>
  <reference>
    <citation>Wynne K, Bloom SR. The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control. Nat Clin Pract Endocrinol Metab. 2006 Nov;2(11):612-20. Review.</citation>
    <PMID>17082808</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2008</study_first_submitted>
  <study_first_submitted_qc>April 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2008</study_first_posted>
  <results_first_submitted>January 19, 2011</results_first_submitted>
  <results_first_submitted_qc>September 6, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 5, 2011</results_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>insulin dependent diabetes</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>detemir</keyword>
  <keyword>levemir</keyword>
  <keyword>glargine</keyword>
  <keyword>lantus</keyword>
  <keyword>insulin</keyword>
  <keyword>appetite</keyword>
  <keyword>satiety</keyword>
  <keyword>centrally acting mediators of satiety</keyword>
  <keyword>three factor eating questionnaire</keyword>
  <keyword>PYY</keyword>
  <keyword>ghrelin</keyword>
  <keyword>leptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Sporadic Newspaper advertisement, Albuquerque Journal, July 2008-July 2010.</recruitment_details>
      <pre_assignment_details>Three weeks of treatment with each insulin (glargine, detemir) in random order, double blind assignment. Doses of glargine and detemir were equivalent and were based upon existing long acting insulin doses. Doses were titrated up to achieve target fasting glucose &lt; 150 mg/dl. Both long acting insulins were given once daily before breakfast.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Insulin Detemir</title>
          <description>These people receive insulin detemir first, then insulin glargine. All subjects received three weeks of therapy with their assigned insulin prior to overnight admission for study.</description>
        </group>
        <group group_id="P2">
          <title>Insulin Glargine</title>
          <description>These people receive insulin glargine first, then insulin detemir. All subjects received three weeks of therapy with their assigned insulin prior to overnight admission for study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Insulin Detemir</title>
          <description>These people receive insulin detemir first, then insulin glargine. All subjects received three weeks of therapy with their assigned insulin prior to overnight admission for study.</description>
        </group>
        <group group_id="B2">
          <title>Insulin Glargine</title>
          <description>These people receive insulin glargine first, then insulin detemir. All subjects received three weeks of therapy with their assigned insulin prior to overnight admission for study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Data for all enrolled subjects in this crossover study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Data for all enrolled subjects.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="14"/>
                    <measurement group_id="B2" value="33" spread="8"/>
                    <measurement group_id="B3" value="35" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Calories Consumed After Fast.</title>
        <description>Total energy ingested following the 24 hour fast.</description>
        <time_frame>Measured after a 24 hour fast, after treatment with study insulin for at least 3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Insulin Detemir</title>
            <description>These people receive insulin detemir first, then insulin glargine. All subjects received three weeks of therapy with their assigned insulin prior to overnight admission for study.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine</title>
            <description>These people receive insulin glargine first, then insulin detemir. All subjects received three weeks of therapy with their assigned insulin prior to overnight admission for study.</description>
          </group>
        </group_list>
        <measure>
          <title>Calories Consumed After Fast.</title>
          <description>Total energy ingested following the 24 hour fast.</description>
          <units>kcal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1418" spread="636"/>
                    <measurement group_id="O2" value="1357" spread="576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Insulin Detemir</title>
          <description>These people receive insulin detemir first, then insulin glargine. All subjects received three weeks of therapy with their assigned insulin prior to overnight admission for study.</description>
        </group>
        <group group_id="E2">
          <title>Insulin Glargine</title>
          <description>These people receive insulin glargine first, then insulin detemir. All subjects received three weeks of therapy with their assigned insulin prior to overnight admission for study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Burge</name_or_title>
      <organization>Univ NM</organization>
      <phone>505-272-4658</phone>
      <email>mburge@salud.unm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

